Antiplatelet Therapy

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow ticagrelor (Brilinta) 90 mg tablets whole. Unlike other P2Y12 inhi...

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with...

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment fol...

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in hospitals across the United States. 

The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and...
ticagrelor, AstraZeneca, FDA, crushing, option
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who...
Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from...
A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established...
ticagrelor, AstraZeneca, FDA, crushing, option
Ticagrelor (Brilinta) 90 mg tablets from AstraZeneca now have FDA approval to be crushed and administered in water by swallowing or via
The Watchman left atrial appendage closure device from Boston Scientific Corp. is a catheter-delivered heart implant designed to close the...
The Xarelto Starter Pack from Janssen Pharmaceuticals Inc. was designed to help simplify the dosing for the initial 30-day treatment period...
Savaysa (edoxaban) tablets from Daiichi Sankyo Co. Ltd. are an oral, once-daily selective factor Xa-inhibitor to reduce the risk of stroke...

Articles

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from...
A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established...
atients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of...
dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length
Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES)...

Video Center

The biggest technology news coming out of the 2015 American College of Cardiology (ACC) annual...
5 days 1 hour ago
It’s been no secret that the American healthcare system needed to change to survive economically...
6 weeks 5 days ago
The silence is deafening. And since radiology associations, physician groups and vendors have yet...
8 weeks 5 days ago
Centricity, webinar, ZFV, ZFP, viewer, remote viewing system, enterprise
Healthcare organizations are demanding more capabilities for image viewers accessed by clinicians. Zero footprint (ZFP) viewers provide imaging tools from...
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...

Comparison Charts

Sorry there is no data available